Nunn Jason Raleigh sold (to issuer) 219,561 shares of ADXN
Nunn Jason Raleigh sold (to issuer) 219,561 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
How this was made
The 30-second read
Why it matters
The transaction is a primary disclosure but small in scale; likely limited effect on the stock.
Market read
Routine insider sale with modest size; minimal trading relevance.
What to watch
No disclosed price; the director may have needed cash for personal reasons.
Background
Addex Therapeutics Ltd. (ADXN) is a biotech listed on Nasdaq. The filing reports a director's complete divestiture of his shares.
Ticker impact
Director Jason Raleigh sold his entire 219,561‑share holding in Addex Therapeutics via a Form 4 filing.
Minor downward pressure; no significant move expected.
The sale is a routine insider transaction of a small size; market may view it as a slight negative cue but not a catalyst.
Market effects
None
None
None
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- CompanyAddex Therapeutics Ltd.
Biotech firm listed on Nasdaq under ticker ADXN.
- InsiderJason Raleigh
Director of Addex who sold his entire shareholding.